These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 15948941)

  • 1. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
    Chui J; Tordoff J; Reith D
    Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.
    Balakrishnan K; Grieve J; Tordoff J; Norris P; Reith D
    J Clin Pharmacol; 2006 Sep; 46(9):1038-43. PubMed ID: 16920899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.
    Balakrishnan K; Tordoff J; Norris P; Reith D
    Br J Clin Pharmacol; 2007 Jan; 63(1):85-91. PubMed ID: 16869822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the pediatric exclusivity provision on children's access to medicines.
    Grieve J; Tordoff J; Reith D; Norris P
    Br J Clin Pharmacol; 2005 Jun; 59(6):730-5. PubMed ID: 15948940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in accessibility to medicines for children in New Zealand: 1998-2002.
    Chui J; Tordoff J; Kennedy J; Reith D
    Br J Clin Pharmacol; 2004 Mar; 57(3):322-7. PubMed ID: 14998428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paediatric formulations--getting to the heart of the problem.
    Standing JF; Tuleu C
    Int J Pharm; 2005 Aug; 300(1-2):56-66. PubMed ID: 15979830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
    Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
    Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands.
    't Jong GW; van der Linden PD; Bakker EM; van der Lely N; Eland IA; Stricker BH; van den Anker JN
    Eur J Clin Pharmacol; 2002 Jul; 58(4):293-7. PubMed ID: 12136376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to prescribing information for paediatric medicines in the USA: post-modernization.
    Young L; Lawes F; Tordoff J; Norris P; Reith D
    Br J Clin Pharmacol; 2009 Mar; 67(3):341-6. PubMed ID: 19220278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007.
    Ragupathy R; Tordoff J; Norris P; Reith D
    Pharm World Sci; 2010 Jun; 32(3):386-93. PubMed ID: 20354788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inappropriate oral formulations and information in paediatric trials.
    Pandit S; Shah U; Kirby DJ; Nunn T; Tuleu C
    Arch Dis Child; 2010 Sep; 95(9):754-6. PubMed ID: 20605870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to new medicines in New Zealand compared to Australia.
    Wonder M; Milne R
    N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of medicines for children.
    Nunn T; Williams J
    Br J Clin Pharmacol; 2005 Jun; 59(6):674-6. PubMed ID: 15948931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Conroy S
    Acta Paediatr; 2003 Apr; 92(4):408-10. PubMed ID: 12801103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The availability and age-appropriateness of medicines authorized for children in The Netherlands.
    van Riet-Nales DA; de Jager KE; Schobben AF; Egberts TC; Rademaker CM
    Br J Clin Pharmacol; 2011 Sep; 72(3):465-73. PubMed ID: 21477143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.